Tweets
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/beh3bEL8fs
Dr. John Cush @RheumNow ( View Tweet )
5 months 1 week ago
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
5 months 1 week ago
Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO
@Janetbirdope pearls in rheumatology.
Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA.
In my clinic ITS inflammatory arthritis to determine etiology .
@RheumNow
#ACR25
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
5 months 1 week ago
Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj
@synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic.
@RheumNow
#ACR25
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
5 months 1 week ago
What's the latest in PsA? https://t.co/I8ZgRQpVy6
Great review for whats new in PsA by @drpnash
Looking forward for Large IL23-Axial study results.
@RheumNow
#ACR25
Links:
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
5 months 1 week ago
Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl
The analogy used by @RheumNow to explain difference between completion versus intention to treat analysis hahahaha. You look good either ways!
@bella_mehta
@RHEUMarampa
@EBRheum
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
5 months 1 week ago
#ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved EULAR response vs PBO. Likely due to restoration of Th17/Treg balance @RheumNow https://t.co/NbwQFqJNho
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
5 months 1 week ago
#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
5 months 1 week ago
#ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ people? Our group compared this with Clinician dx -> high specificity(93.8%); low sensitivity(79.3%). Might be a cause why SMILE HCQ RCT failed in At-Risk @RheumNow https://t.co/6GNU2B2wvj
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
5 months 1 week ago
Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts
JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04)
Individualize tx. consider potential complications
#ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW
Links:
sheila @RHEUMarampa ( View Tweet )
5 months 1 week ago
Sex differences in đź’Š d/c in axSpA from the RISE registry
🔅Females - ⬆️discontinuation risks for TNFi
đź”…No sex differences seen in dc risks for IL17i and JAKis
đź”…Young females discontinued faster than males
Gender diff in SpA can guide tx decisions
#ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI
Links:
sheila @RHEUMarampa ( View Tweet )
5 months 1 week ago
Can we catch PsA before it starts?
My take on #ABSTRACT0877 for #ACR25
@RheumNow
https://t.co/Rw2gJ4XSsz
Aurelie Najm @AurelieRheumo ( View Tweet )
5 months 1 week ago
